Latest & greatest articles for atorvastatin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on atorvastatin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on atorvastatin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for atorvastatin

61. Evaluation of the cost savings and clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a primary care setting Full Text available with Trip Pro

Evaluation of the cost savings and clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a primary care setting Evaluation of the cost savings and clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a primary care setting Evaluation of the cost savings and clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a primary care setting Usher-Smith J (...) A, Ramsbottom T, Pearmain H, Kirby M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study examined switching the patients' medication from 10 or 20g atorvastatin to 20 or 40 mg simvastatin for the treatment of high cholesterol

2007 NHS Economic Evaluation Database.

62. Cost-effectiveness of primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes: results from the Collaborative Atorvastatin Diabetes Study (CARDS)

Cost-effectiveness of primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes: results from the Collaborative Atorvastatin Diabetes Study (CARDS) Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2007 NHS Economic Evaluation Database.

63. A model for assessing the cost-effectiveness of atorvastatin and simvastatin in achieving Canadian low-density lipoprotein cholesterol targets

A model for assessing the cost-effectiveness of atorvastatin and simvastatin in achieving Canadian low-density lipoprotein cholesterol targets A model for assessing the cost-effectiveness of atorvastatin and simvastatin in achieving Canadian low-density lipoprotein cholesterol targets A model for assessing the cost-effectiveness of atorvastatin and simvastatin in achieving Canadian low-density lipoprotein cholesterol targets Lachaine J, Merikle E, Tarride J E, Montpetit M, Rinfret S Record (...) Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study compared the cost-effectiveness of two cholesterol-lowering pharmaceuticals, atorvastatin (10 to 80 mg/day) and generic simvastatin (10 to 80 mg/day). Statin medications treat

2007 NHS Economic Evaluation Database.

64. Cost-effectiveness of high-dose atorvastatin compared with regular dose simvastatin Full Text available with Trip Pro

Cost-effectiveness of high-dose atorvastatin compared with regular dose simvastatin Cost-effectiveness of high-dose atorvastatin compared with regular dose simvastatin Cost-effectiveness of high-dose atorvastatin compared with regular dose simvastatin Lindgren P, Graff J, Olsson A G, Pedersen T J, Jonsson B Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results (...) and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study evaluated the long-term cost-effectiveness of two options for the secondary prevention of cardiovascular disease in patients, under 80 years old, who had experienced acute myocardial infarction. At a willingness-to-pay of 50,000 Euros per quality-adjusted life-year, atorvastatin was cost-effective compared with simvastatin in Denmark, Norway and Sweden, while in Finland

2007 NHS Economic Evaluation Database.

65. A dose-specific meta-analysis of lipid changes in randomized controlled trials of atorvastatin and simvastatin

A dose-specific meta-analysis of lipid changes in randomized controlled trials of atorvastatin and simvastatin Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2007 DARE.

66. Cost-effectiveness and budget impact analysis of rosuvastatin and atorvastatin for LDL-cholesterol and cardiovascular events lowering within the SUS scenario

Cost-effectiveness and budget impact analysis of rosuvastatin and atorvastatin for LDL-cholesterol and cardiovascular events lowering within the SUS scenario Cost-effectiveness and budget impact analysis of rosuvastatin and atorvastatin for LDL-cholesterol and cardiovascular events lowering within the SUS scenario Cost-effectiveness and budget impact analysis of rosuvastatin and atorvastatin for LDL-cholesterol and cardiovascular events lowering within the SUS scenario Araujo D V, Bahia L (...) , Souza C P, Pavao A L Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study investigated the cost-effectiveness of rosuvastatin versus atorvastatin for lowering low-density lipoprotein-cholesterol and avoiding future cardiovascular

2007 NHS Economic Evaluation Database.

67. Amlodipine besylate/ atorvastatin calcium

Amlodipine besylate/ atorvastatin calcium Common Drug Review CEDAC Meeting – April 19, 2006 Page 1 of 1 Notice of CEDAC Final Recommendation – May 17, 2006 CEDAC FINAL RECOMMENDATION and REASONS for RECOMMENDATION AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM (Caduet ™ – Pfizer Canada Inc.) Description: Caduet ™ is a fixed dose combination of amlodipine and atorvastatin and is approved for use in patients for whom treatment with both amlodipine and atorvastatin is appropriate, specifically (...) , patients at cardiovascular risk. Dosage Forms: Tablets containing amlodipine/atorvastatin in the following combinations: 5/10 mg, 5/20 mg, 5/40 mg, 5/80 mg, 10/10 mg, 10/20 mg, 10/40 mg and 10/80 mg. Recommendation: The Canadian Expert Drug Advisory Committee (CEDAC) recommends that Caduet ™ be listed for patients who have been titrated to a stable combination of the separate components, amlodipine and atorvastatin. Reasons for the Recommendation: 1. There were no randomized controlled trials (RCTs

2006 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

68. Atorvastatin reduced major cardiovascular disease events in type 2 diabetes mellitus Full Text available with Trip Pro

Atorvastatin reduced major cardiovascular disease events in type 2 diabetes mellitus Atorvastatin reduced major cardiovascular disease events in type 2 diabetes mellitus | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers (...) of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Atorvastatin reduced major cardiovascular disease events in type 2 diabetes mellitus Article Text Therapeutics Atorvastatin reduced major cardiovascular disease events in type 2 diabetes mellitus Free Apoor S Gami , MD

2006 Evidence-Based Medicine

69. Are statins created equal: evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention

Are statins created equal: evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention Are statins created equal: evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention Are statins created equal: evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention Zhou Z, Rahme E, Pilote L CRD summary This review assessed (...) the relative efficacy of pravastatin, simvastatin and atorvastatin. The authors concluded that the evidence suggests there is no statistically significant difference in long-term cardiovascular outcomes between standard doses of these statins. Statements on relative efficacy were based on indirect comparisons, thus the authors' cautious conclusion appears appropriate. Authors' objectives To assess the relative efficacy of pravastatin, simvastatin and atorvastatin. Searching MEDLINE and the Cochrane

2006 DARE.

70. Cost-effectiveness of rosuvastatin, atorvastatin, simvastatin, pravastatin and fluvastatin for the primary prevention of CHD in the UK

Cost-effectiveness of rosuvastatin, atorvastatin, simvastatin, pravastatin and fluvastatin for the primary prevention of CHD in the UK Cost-effectiveness of rosuvastatin, atorvastatin, simvastatin, pravastatin and fluvastatin for the primary prevention of CHD in the UK Cost-effectiveness of rosuvastatin, atorvastatin, simvastatin, pravastatin and fluvastatin for the primary prevention of CHD in the UK Davies A, Hutton J, O'Donnell J, Kingslake S Record Status This is a critical abstract (...) rosuvastatin (ROS), atorvastatin (ATO), simvastatin (SIM), pravastatin (PRA) and fluvastatin (FLU). Initial doses were 10 mg for ROS, ATO and SIM, 20 mg for PRA, and 40 mg for FLU. Patients who failed to reach the target cholesterol level with the initial dosage where titrated to the next highest dosage (20 and 40 mg for ROS and PRA, 20, 40 and 80 mg for ATO and SIM, and 40 and 80 mg for FLU). Type of intervention Primary prevention. Economic study type Cost-utility analysis. Study population The study

2006 NHS Economic Evaluation Database.

71. Evaluation of the effects of statins (with particular consideration of atorvastatin)

Evaluation of the effects of statins (with particular consideration of atorvastatin) Evaluation of the effects of statins (with particular consideration of atorvastatin) Evaluation of the effects of statins (with particular consideration of atorvastatin) Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has (...) been made for the HTA database. Citation Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Evaluation of the effects of statins (with particular consideration of atorvastatin) Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). 2006 Authors' objectives The aim of this systematic literature review is to describe and evaluate the current evidence available on the therapeutic effects of statins, focussing on the aspects described above

2006 Health Technology Assessment (HTA) Database.

72. High-dose atorvastatin after stroke or transient ischemic attack. (Abstract)

High-dose atorvastatin after stroke or transient ischemic attack. Statins reduce the incidence of strokes among patients at increased risk for cardiovascular disease; whether they reduce the risk of stroke after a recent stroke or transient ischemic attack (TIA) remains to be established.We randomly assigned 4731 patients who had had a stroke or TIA within one to six months before study entry, had low-density lipoprotein (LDL) cholesterol levels of 100 to 190 mg per deciliter (2.6 to 4.9 mmol (...) per liter), and had no known coronary heart disease to double-blind treatment with 80 mg of atorvastatin per day or placebo. The primary end point was a first nonfatal or fatal stroke.The mean LDL cholesterol level during the trial was 73 mg per deciliter (1.9 mmol per liter) among patients receiving atorvastatin and 129 mg per deciliter (3.3 mmol per liter) among patients receiving placebo. During a median follow-up of 4.9 years, 265 patients (11.2 percent) receiving atorvastatin and 311 patients

2006 NEJM Controlled trial quality: predicted high

73. High dose atorvastatin was superior to standard dose pravastatin in reducing death or major CV events in acute coronary syndrome Full Text available with Trip Pro

High dose atorvastatin was superior to standard dose pravastatin in reducing death or major CV events in acute coronary syndrome High dose atorvastatin was superior to standard dose pravastatin in reducing death or major CV events in acute coronary syndrome | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our (...) . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here High dose atorvastatin was superior to standard dose pravastatin in reducing death or major CV events in acute coronary syndrome

2005 Evidence-Based Medicine

74. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. Full Text available with Trip Pro

Intensive lipid lowering with atorvastatin in patients with stable coronary disease. Previous trials have demonstrated that lowering low-density lipoprotein (LDL) cholesterol levels below currently recommended levels is beneficial in patients with acute coronary syndromes. We prospectively assessed the efficacy and safety of lowering LDL cholesterol levels below 100 mg per deciliter (2.6 mmol per liter) in patients with stable coronary heart disease (CHD).A total of 10,001 patients (...) with clinically evident CHD and LDL cholesterol levels of less than 130 mg per deciliter (3.4 mmol per liter) were randomly assigned to double-blind therapy and received either 10 mg or 80 mg of atorvastatin per day. Patients were followed for a median of 4.9 years. The primary end point was the occurrence of a first major cardiovascular event, defined as death from CHD, nonfatal non-procedure-related myocardial infarction, resuscitation after cardiac arrest, or fatal or nonfatal stroke.The mean LDL

2005 NEJM Controlled trial quality: predicted high

75. Rosuvastatin is cost-effective in treating patients to low-density lipoprotein-cholesterol goals compared with atorvastatin, pravastatin and simvastatin: analysis of the STELLAR trial

Rosuvastatin is cost-effective in treating patients to low-density lipoprotein-cholesterol goals compared with atorvastatin, pravastatin and simvastatin: analysis of the STELLAR trial Rosuvastatin is cost-effective in treating patients to low-density lipoprotein-cholesterol goals compared with atorvastatin, pravastatin and simvastatin: analysis of the STELLAR trial Rosuvastatin is cost-effective in treating patients to low-density lipoprotein-cholesterol goals compared with atorvastatin (...) , pravastatin and simvastatin: analysis of the STELLAR trial Hirsch M, O'Donnell J C, Jones P Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of rosuvastatin (10 - 40 mg/day), atorvastatin (10 - 80 mg/day), pravastatin (10 - 40 mg

2005 NHS Economic Evaluation Database.

76. Cost effectiveness of rosuvastatin in treating patients to low-density lipoprotein cholesterol goals compared with atorvastatin, pravastatin, and simvastatin (a US Analysis of the STELLAR Trial)

Cost effectiveness of rosuvastatin in treating patients to low-density lipoprotein cholesterol goals compared with atorvastatin, pravastatin, and simvastatin (a US Analysis of the STELLAR Trial) Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2005 NHS Economic Evaluation Database.

77. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. Full Text available with Trip Pro

High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. Evidence suggests that more intensive lowering of low-density lipoprotein cholesterol (LDL-C) than is commonly applied clinically will provide further benefit in stable coronary artery disease.To compare the effects of 2 strategies of lipid lowering on the risk of cardiovascular disease among patients with a previous myocardial infarction (MI (...) ).The IDEAL study, a prospective, randomized, open-label, blinded end-point evaluation trial conducted at 190 ambulatory cardiology care and specialist practices in northern Europe between March 1999 and March 2005 with a median follow-up of 4.8 years, which enrolled 8888 patients aged 80 years or younger with a history of acute MI.Patients were randomly assigned to receive a high dose of atorvastatin (80 mg/d; n = 4439), or usual-dose simvastatin (20 mg/d; n = 4449).Occurrence of a major coronary event

2005 JAMA Controlled trial quality: predicted high

78. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. (Abstract)

Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. Statins reduce the incidence of cardiovascular events in persons with type 2 diabetes mellitus. However, the benefit of statins in such patients receiving hemodialysis, who are at high risk for cardiovascular disease and death, has not been examined.We conducted a multicenter, randomized, double-blind, prospective study of 1255 subjects with type 2 diabetes mellitus receiving maintenance hemodialysis who were (...) randomly assigned to receive 20 mg of atorvastatin per day or matching placebo. The primary end point was a composite of death from cardiac causes, nonfatal myocardial infarction, and stroke. Secondary end points included death from all causes and all cardiac and cerebrovascular events combined.After four weeks of treatment, the median level of low-density lipoprotein cholesterol was reduced by 42 percent among patients receiving atorvastatin, and among those receiving placebo it was reduced by 1.3

2005 NEJM Controlled trial quality: predicted high

79. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. (Abstract)

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Type 2 diabetes is associated with a substantially increased risk of cardiovascular disease, but the role of lipid-lowering therapy with statins for the primary prevention of cardiovascular disease in diabetes is inadequately defined. We aimed to assess the effectiveness of atorvastatin 10 mg daily (...) for primary prevention of major cardiovascular events in patients with type 2 diabetes without high concentrations of LDL-cholesterol.2838 patients aged 40-75 years in 132 centres in the UK and Ireland were randomised to placebo (n=1410) or atorvastatin 10 mg daily (n=1428). Study entrants had no documented previous history of cardiovascular disease, an LDL-cholesterol concentration of 4.14 mmol/L or lower, a fasting triglyceride amount of 6.78 mmol/L or less, and at least one of the following

2004 Lancet Controlled trial quality: predicted high

80. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. (Abstract)

Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Rheumatoid arthritis is characterised by inflammatory synovitis, articular destruction, and accelerated atherogenesis. HMG-CoA (3-hydroxy-3-methylglutarylcoenzyme A) reductase inhibitors (statins) mediate clinically significant vascular risk reduction in patients without inflammatory disease and might have immunomodulatory function. We postulated that statins might reduce inflammatory (...) factors in rheumatoid arthritis and modify surrogates for vascular risk.116 patients with rheumatoid arthritis were randomised in a double-blind placebo-controlled trial to receive 40 mg atorvastatin or placebo as an adjunct to existing disease-modifying antirheumatic drug therapy. Patients were followed up over 6 months and disease activity variables and circulating vascular risk factors were measured. Coprimary outcomes were change in disease activity score (DAS28) and proportion meeting EULAR

2004 Lancet Controlled trial quality: predicted high